Protagonist Therapeutics, Inc.

NASDAQ (USD): Protagonist Therapeutics, Inc. (PTGX)

Last Price

56.01

Today's Change

+0.32 (0.57%)

Day's Change

55.69 - 57.22

Trading Volume

244,856

Overview

Market Cap

0

Shares Outstanding

0

Avg Volume

0

Avg Price (50 Days)

0.00

Avg Price (200 Days)

0.00

PE Ratio

0.00

EPS

0.00

Earnings Announcement

Previous Close

0.00

Open

0.00

Day's Range

0.0 - 0.0

Year Range

0.0 - 0.0

Trading Volume

0

Price Change Highlight

1 Day Change

5 Day Change

1 Month Change

3 Month Change

6 Month Change

Ytd Change

1 Year Change

3 Year Change

5 Year Change

10 Year Change

Max Change

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment